1994
DOI: 10.1006/abio.1994.1060
|View full text |Cite
|
Sign up to set email alerts
|

Release of Proteins and Peptides from Fusion Proteins Using a Recombinant Plant Virus Proteinase

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
165
0
3

Year Published

1996
1996
2008
2008

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 280 publications
(168 citation statements)
references
References 0 publications
0
165
0
3
Order By: Relevance
“…ALP and CLP36 fragments were cloned in a modified pET24d vector (Novagen, Merck Biosciences, Schwalbach, Germany). All inserts in the modified pET24d vector contained an N-terminal His 6 tag followed by a tobacco etch virus protease recognition site (27) and three extra residues (ENLYFQ2GAMG, 2 denotes the tobacco etch virus cleavage site). Full human ␣-actinin 2A (M86406) (28) in modified pET8c (Novagen) vector (described in Djinovic-Carugo et al (3)) was used to generate shorted fragments of ␣-actinin 2 to the pET8c or to the pET24d vector.…”
Section: Methodsmentioning
confidence: 99%
“…ALP and CLP36 fragments were cloned in a modified pET24d vector (Novagen, Merck Biosciences, Schwalbach, Germany). All inserts in the modified pET24d vector contained an N-terminal His 6 tag followed by a tobacco etch virus protease recognition site (27) and three extra residues (ENLYFQ2GAMG, 2 denotes the tobacco etch virus cleavage site). Full human ␣-actinin 2A (M86406) (28) in modified pET8c (Novagen) vector (described in Djinovic-Carugo et al (3)) was used to generate shorted fragments of ␣-actinin 2 to the pET8c or to the pET24d vector.…”
Section: Methodsmentioning
confidence: 99%
“…Furthermore, the forward primer 5 0 -CATTCCATGGGTTCCGACGACCAGCTGGTG (NcoI restriction site in bold) and reverse primer 5 0 -TAAGGTACCTCAGCGGCC-GGAGTTGGCGAGTTTCTC were used to introduce an extra arginine residue (in bold) at the C-terminal end of the protein construct (construct MafB 211-305,C298S,R306 ; all primers were synthesized by MWG-Biotech). The amplified PCR product was subcloned into a pETM-11 expression vector which encodes an N-terminal 6ÂHis tag and a TEV cleavage site for subsequent affinity-tag removal by TEV protease (Parks et al, 1994). Optimal recombinant protein expression was obtained using Escherichia coli strain BL21(DE3) Codon Plus RIL (Stratagene).…”
Section: Cloning and Expressionmentioning
confidence: 99%
“…One method of tag removal is through the use of the tobacco etch virus (TEV) protease. TEV protease has become one of the proteases of choice for cleaving fusion proteins due to its high degree of specificity, its resistance to many protease inhibitors used in protein purification, and the ease of separation of both the protease and affinity tag from the protein of interest (Parks et al, 1994). Additionally, improvement to the ability to purify large amounts of TEV protease (Blommel & Fox, 2007;Lucast et al, 2001;van den Berg et al, 2006) can make the TEV protease a relatively inexpensive option for cleavage of fusion proteins when compared to other commercially available options.…”
Section: Introductionmentioning
confidence: 99%